Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a capital markets day on October 20, 2020, starting at 8:15 a.m. ET. The event will be hosted by Cameron Reynolds, CEO, and feature Dr. Heather Wilson-Robles, presenting data on the Nu.Q™ Vet Cancer Screening Test. Attendees will receive updates on Volition's clinical trials and developments. Volition specializes in epigenetics, focusing on blood tests for early cancer diagnosis, with operations in Belgium, Texas, London, and Singapore.
VolitionRx Limited (NYSE AMERICAN: VNRX) will present at five virtual conferences in September 2020. CEO Cameron Reynolds and EVP Scott Powell will share insights on the company’s milestones and financial results. Key conferences include LD Micro 500 on September 1, GCFF on September 10, Cantor Healthcare on September 15, Life Sciences Forum on September 17, and Oppenheimer Summit on September 21. The company focuses on developing cost-effective blood tests for early cancer diagnosis, utilizing its Nucleosomics™ technology.
On August 13, 2020, VolitionRx Limited (VNRX) announced its financial results for Q2 2020, revealing cash and cash equivalents of approximately $21.3 million, up from $12 million in the previous quarter. The company raised $13.8 million through public offerings and an additional $4.7 million via an ATM program. Focused on cancer diagnostics, the company is also exploring applications for COVID-19 detection. Positive preliminary results suggest the potential for Nu.Q™ to serve as a biomarker for COVID-19 severity. A new production facility in Belgium aims to enhance supply chain flexibility.
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a conference call on August 14, 2020, at 8:30 a.m. Eastern time, to discuss its second quarter 2020 financial results and provide a business update. CEO Cameron Reynolds, CFO David Vanston, and EVP of Investor Relations Scott Powell will discuss recent developments, ongoing clinical trials, and upcoming milestones. Investors can access the live call on Volition’s investor relations page, with a replay available until August 28, 2020. Volition specializes in blood tests for early disease diagnosis through its Nucleosomics technology.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its inclusion in the Russell 3000® and Russell Microcap® Indexes effective June 26, 2020. This recognition highlights the company's progress in developing cost-effective blood tests for cancer diagnosis. CEO Cameron Reynolds emphasized the potential for increased visibility and liquidity in shares following this index inclusion. The Russell Indexes represent approximately $9 trillion in assets, promoting further growth opportunities for Volition.